Aro Biotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Aro Biotherapeutics's estimated annual revenue is currently $4.3M per year.
- Aro Biotherapeutics's estimated revenue per employee is $77,500
- Aro Biotherapeutics's total funding is $101M.
Employee Data
- Aro Biotherapeutics has 56 Employees.
- Aro Biotherapeutics grew their employee count by -11% last year.
Aro Biotherapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $3.3M | 21 | -5% | N/A | N/A |
#3 | $1.4M | 9 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 25% | N/A | N/A |
#5 | $10.5M | 68 | 1% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4.8M | 31 | -11% | N/A | N/A |
#8 | $1.6M | 10 | 11% | N/A | N/A |
#9 | $7.4M | 48 | -11% | N/A | N/A |
#10 | $1.9M | 12 | -25% | N/A | N/A |
What Is Aro Biotherapeutics?
Unlocking the Potential of Genetic Medicines Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
keywords:N/A$101M
Total Funding
56
Number of Employees
$4.3M
Revenue (est)
-11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aro Biotherapeutics News
Tortorici is the Vice President, Clinical Pharmacology & Non-Clinical Development at Aro Biotherapeutics, and an Advisory Council Member for the...
Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $11.4M | 56 | 30% | N/A |
#2 | $3.5M | 56 | 14% | N/A |
#3 | $6.6M | 56 | N/A | N/A |
#4 | N/A | 56 | 12% | N/A |
#5 | $221.1M | 56 | -2% | N/A |